|
|
||||||||
1 From the Neurobiology Center, National Autonomous University of Mexico, Querétaro, Mexico; and the 2 Institute for Biomedical Aging Research, Austrian Academy of Sciences, Innsbruck, Austria.
PURPOSE. The cornea is an avascular organ, where induction of new blood vessels involves the turn-on of proangiogenic factors and/or the turn-off of antiangiogenic regulators. Prolactin (PRL) fragments of 14 kDa and 16 kDa bind to endothelial cell receptors and inhibit angiogenesis. This study was designed to determine whether antiangiogenic PRL-like molecules are involved in cornea avascularity.
METHODS. Sixteen-kDa PRL and basic fibroblast growth factor (bFGF) or anti-PRL antibodies were placed into rat cornea micropockets and neovascularization evaluated by the optical density associated with capillaries stained by the peroxidase reaction and by the number of vessels growing into the implants. Prolactin receptors in corneal epithelium were investigated by immunocytochemistry.
RESULTS. bFGF induced a dose-dependent stimulation of corneal neovascularization. This effect was inhibited by coadministration of 16-kDa PRL, as indicated by a 65% reduction in vessel density and a 50% decrement in the incidence of angiogenic responses. Corneal angiogenic reactions of different intensities were induced by implantation of polyclonal and monoclonal anti-PRL antibodies. Corneal epithelial cells were labeled by several anti-PRL receptor monoclonal antibodies.
CONCLUSIONS. These findings show that exogenous 16-kDa PRL inhibits bFGF-induced corneal neovascularization and suggest that PRL-like molecules with antiangiogenic actions function in the cornea. PRL receptors in the corneal epithelium may imply that PRL in the cornea derives from lacrimal PRL internalized through an intracellular pathway. These observations are consistent with the notion that members of the PRL family are potential regulators of corneal angiogenesis.
This article has been cited by other articles:
![]() |
S.-H. Lee, J. Kunz, S.-H. Lin, and L.-y. Yu-Lee 16-kDa Prolactin Inhibits Endothelial Cell Migration by Down-Regulating the Ras-Tiam1-Rac1-Pak1 Signaling Pathway Cancer Res., November 15, 2007; 67(22): 11045 - 11053. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Macotela, M. B. Aguilar, J. Guzman-Morales, J. C. Rivera, C. Zermeno, F. Lopez-Barrera, G. Nava, C. Lavalle, G. M. de la Escalera, and C. Clapp Matrix metalloproteases from chondrocytes generate an antiangiogenic 16 kDa prolactin J. Cell Sci., May 1, 2006; 119(9): 1790 - 1800. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ueda, U. Ozerdem, Y.-H. Chen, M. Yao, K. T. Huang, H. Sun, M. Martins-Green, P. Bartolini, and A. M Walker A molecular mimic demonstrates that phosphorylated human prolactin is a potent anti-angiogenic hormone. Endocr. Relat. Cancer, March 1, 2006; 13(1): 95 - 111. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-h. Lee, M. Nishino, T. Mazumdar, G. E. Garcia, M. Galfione, F. L. Lee, C. L. Lee, A. Liang, J. Kim, L. Feng, et al. 16-kDa Prolactin Down-Regulates Inducible Nitric Oxide Synthase Expression through Inhibition of the Signal Transducer and Activator of Transcription 1/IFN Regulatory Factor-1 Pathway Cancer Res., September 1, 2005; 65(17): 7984 - 7992. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Aranda, J. C. Rivera, M. C. Jeziorski, J. Riesgo-Escovar, G. Nava, F. Lopez-Barrera, H. Quiroz-Mercado, P. Berger, G. Martinez de la Escalera, and C. Clapp Prolactins Are Natural Inhibitors of Angiogenesis in the Retina Invest. Ophthalmol. Vis. Sci., August 1, 2005; 46(8): 2947 - 2953. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Horiguchi, S Yagi, K Ono, Y Nishiura, M Tanaka, M Ishida, and T Harigaya Prolactin gene expression in mouse spleen helper T cells J. Endocrinol., December 1, 2004; 183(3): 639 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Gonzalez, A. M. Corbacho, J. P. Eiserich, C. Garcia, F. Lopez-Barrera, V. Morales-Tlalpan, A. Barajas-Espinosa, M. Diaz-Munoz, R. Rubio, S.-H. Lin, et al. 16K-Prolactin Inhibits Activation of Endothelial Nitric Oxide Synthase, Intracellular Calcium Mobilization, and Endothelium-Dependent Vasorelaxation Endocrinology, December 1, 2004; 145(12): 5714 - 5722. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Duenas, J. C. Rivera, H. Quiroz-Mercado, J. Aranda, Y. Macotela, P. M. de Oca, F. Lopez-Barrera, G. Nava, J. L. Guerrero, A. Suarez, et al. Prolactin in Eyes of Patients with Retinopathy of Prematurity: Implications for Vascular Regression Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2049 - 2055. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Pan, N.-Q.-N. Nguyen, H. Yoshida, F. Bentzien, L. C. Shaw, F. Rentier-Delrue, J. A. Martial, R. Weiner, I. Struman, and M. B. Grant Molecular Targeting of Antiangiogenic Factor 16K hPRL Inhibits Oxygen-Induced Retinopathy in Mice Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2413 - 2419. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kim, W. Luo, D.-T. Chen, K. Earley, J. Tunstead, L.-Y. Yu-Lee, and S.-H. Lin Antitumor Activity of the 16-kDa Prolactin Fragment in Prostate Cancer Cancer Res., January 15, 2003; 63(2): 386 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. K. Ambati, A. M. Joussen, J. Ambati, Y. Moromizato, C. Guha, K. Javaherian, S. Gillies, M. S. O'Reilly, and A. P. Adamis Angiostatin Inhibits and Regresses Corneal Neovascularization Arch Ophthalmol, August 1, 2002; 120(8): 1063 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Bentzien, I. Struman, J.-F. Martini, J. Martial, and R. Weiner Expression of the Antiangiogenic Factor 16K hPRL in Human HCT116 Colon Cancer Cells Inhibits Tumor Growth in Rag1-/- Mice Cancer Res., October 1, 2001; 61(19): 7356 - 7362. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ochoa, P. Montes de Oca, J. C. Rivera, Z. Dueñas, G. Nava, G. M. de la Escalera, and C. Clapp Expression of Prolactin Gene and Secretion of Prolactin by Rat Retinal Capillary Endothelial Cells Invest. Ophthalmol. Vis. Sci., June 1, 2001; 42(7): 1639 - 1645. [Abstract] [Full Text] |
||||
![]() |
D. Coss, L. Yang, C. B. Kuo, X. Xu, R. A. Luben, and A. M. Walker Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat Am J Physiol Endocrinol Metab, December 1, 2000; 279(6): E1216 - E1225. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |